Quantum Biopharma (QNTM) Non-Current Assets (2018 - 2026)
Quantum Biopharma (QNTM) posted Non-Current Assets of $4.6 million for Q1 2026, down 2.68% sequentially from $4.7 million in Q4 2025, and down 7.78% YoY from $4.9 million in Q1 2025.
Quantum Biopharma (QNTM) Non-Current Assets (2018 - 2026) Analysis & Trends
Quantum Biopharma has reported Non-Current Assets for 9 years, with the latest figure at $4.6 million in Q1 2026.
- Quarterly Non-Current Assets fell 7.78% year-over-year to $4.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $19.0 million (down 6.92% YoY) and the FY2025 annual result came in at $4.7 million, down 7.58% from the prior year.
- Non-Current Assets retreated to $4.6 million in Q1 2026 per QNTM's latest filing, from $4.7 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $20.6 million in Q4 2022 and troughed at $4.6 million in Q1 2026.
- A 5-year average of $6.6 million and a median of $5.0 million in 2024 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets climbed 20.73% in 2022, then slumped 68.92% in 2023.
- Over 5 years, Non-Current Assets stood at $20.6 million in 2022, then plunged by 68.92% to $6.4 million in 2023, then retreated by 20.71% to $5.1 million in 2024, then declined by 7.58% to $4.7 million in 2025, then dropped by 2.68% to $4.6 million in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $4.6 million, $4.7 million, and $4.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 18.06 Bn |
| 10 | Quantum Biopharma | 15.44 Mn | 11.80 Mn | - | 4.43 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 4.43 Mn |
| Mar 31, 2026 | 4.56 Mn |
| Dec 31, 2025 | 4.68 Mn |
| Sep 30, 2025 | 4.81 Mn |
| Jun 30, 2025 | 4.95 Mn |
| Mar 31, 2025 | 4.94 Mn |
| Dec 31, 2024 | 5.07 Mn |
| Sep 30, 2024 | 5.18 Mn |
| Jun 30, 2024 | 5.22 Mn |
| Dec 31, 2023 | 6.39 Mn |
| Dec 31, 2022 | 20.56 Mn |
| Dec 31, 2021 | 17.03 Mn |
| Dec 31, 2020 | 15.10 Mn |
| Dec 31, 2019 | 34.90 Mn |
| Dec 31, 2018 | 22.88 Mn |